Trial Profile
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology Revised Protocol Number 04, incorporating Amendment 05 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 07-Jan-09)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pegdinetanib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 19 Jul 2019 As per European Clinical Trials Database record, trial is completed in UK (End Date: 28 Aug 2013).
- 01 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov record.
- 11 Oct 2012 Planned number of patients changed from 254 to 282.